MedPacto Inc

MedPacto operates with a highly liquid capital structure, as evidenced by a current ratio of 32.86, indicating strong short-term liquidity. The company holds KRW 11,997,347,140 in cash and equivalents, which significantly exceeds its total liabilities of KRW 2,681,222,550. Despite this, the company reports negative operating and net income, with operating income of -KRW 13,879,827,120 and net income of -KRW 12,810,783,520, reflecting ongoing operational losses. Profitability metrics are weak, with a return on equity of -27.86% and a return on assets of -26.33%, both significantly below the industry median for biotechnology firms. These figures suggest the company is not generating returns on its equity or asset base and is underperforming relative to its peers. The company's revenue is concentrated in a single business segment focused on biopharmaceutical R&D, with no disclosed geographic diversification. This lack of diversification increases exposure to regulatory, clinical, and market risks in the Korean biotech sector. Growth trajectory is constrained by negative operating and free cash flows, with operating cash flow of -KRW 13,389,815,130 and free cash flow of -KRW 11,897,974,540. The company has not disclosed any revenue growth in recent periods, and no forward-looking guidance is available to suggest an improvement in cash flow generation. Risk factors include the absence of immediate liquidity or dilution flags, with a low risk rating for both. The company has not issued any recent equity or debt that would suggest dilution pressure, and its debt-to-equity ratio of 0.04 indicates minimal leverage. However, the ongoing operational losses and negative cash flows remain a concern for long-term sustainability. Recent events include no disclosed filings or transcripts that would indicate significant corporate developments. The company's focus remains on R&D for anticancer drugs and diagnostic kits, with no recent clinical trial results or regulatory approvals reported.